Effects of expressive helping writing during stem cell transplant: Randomized controlled trial.

Christine Rini, George Luta, Deniz Ozisik, Scott D Rowley, Annette L Stanton, Heiddis Valdimarsdottir, Jane Austin, Betina Yanez, Kristi D Graves
Author Information
  1. Christine Rini: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine. ORCID
  2. George Luta: Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center.
  3. Deniz Ozisik: Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center.
  4. Scott D Rowley: Department of Oncology, Georgetown University Lombardi Comprehensive Cancer Center.
  5. Annette L Stanton: Department of Psychology, University of California at Los Angeles.
  6. Heiddis Valdimarsdottir: Department of Psychology, Reykjavik University.
  7. Jane Austin: Department of Psychology, William Paterson University.
  8. Betina Yanez: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine.
  9. Kristi D Graves: Department of Oncology, Georgetown University Lombardi Comprehensive Cancer Center.

Abstract

OBJECTIVE: Most cancer patients undergoing hematopoietic stem cell transplant report elevated symptoms and reduced health-related quality of life during peritransplant. These concerns can become persistent. A prior randomized controlled trial showed that expressive helping-a low-burden, brief intervention combining expressive writing with a novel peer support writing exercise-reduced psychological distress and physical symptoms in long-term transplant survivors with moderate/high persistent symptoms. The Writing for Insight, Strength, and Ease trial evaluated the use of expressive helping during peritransplant, when symptoms peak and early intervention could prevent the development of persistent symptoms.
METHOD: Three hundred sixty-six adult blood cancer patients (44.3% female, 74.6% White, 13.4% Black, 11.5% Hispanic/Latinx) scheduled for allogeneic (33.9%) or autologous (66.1%) transplant were randomized to complete either expressive helping or a neutral writing task in four writing sessions beginning pretransplant and ending 4 weeks posthospital discharge. Symptom severity (primary outcome), distress (depressive symptoms, generalized and cancer-specific anxiety), health-related quality of life, and fatigue were measured in multiple assessments from prerandomization to 12 months postintervention. Primary endpoints at 3 and 12 months postintervention estimated short- and long-term intervention effects. Moderation analyses explored subgroup differences in intervention efficacy.
RESULTS: Mixed models with repeated measures analyses revealed no statistically or clinically significant intervention effects on primary or secondary outcomes. Moderation analyses did not identify subgroups of participants who benefitted from the intervention.
CONCLUSION: Findings do not support use of expressive helping during peritransplant. We recommend that survivors with persistent symptoms complete expressive helping at least 9 months posttransplant, consistent with evidence from a prior trial. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

References

  1. J Broadcast Electron Media. 2020;64(2):277-297 [PMID: 33584002]
  2. Psychol Med. 2021 Feb 26;:1-13 [PMID: 33634766]
  3. J Community Psychol. 1983 Jan;11(1):58-66 [PMID: 10259114]
  4. Biol Blood Marrow Transplant. 2016 Nov;22(11):2077-2083 [PMID: 27538374]
  5. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD007944 [PMID: 20238359]
  6. J Clin Epidemiol. 2019 Jun;110:74-81 [PMID: 30826377]
  7. Curr Psychiatry Rep. 2016 Feb;18(2):20 [PMID: 26800995]
  8. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):220-227 [PMID: 28641097]
  9. J Biomed Inform. 2009 Apr;42(2):377-81 [PMID: 18929686]
  10. Arch Intern Med. 2006 May 22;166(10):1092-7 [PMID: 16717171]
  11. J Pain Symptom Manage. 1997 Feb;13(2):63-74 [PMID: 9095563]
  12. Biol Blood Marrow Transplant. 2014 Mar;20(3):387-95 [PMID: 24355521]
  13. Qual Life Res. 2009 Sep;18(7):873-80 [PMID: 19543809]
  14. Psychooncology. 2017 Sep;26(9):1361-1368 [PMID: 27145447]
  15. Support Care Cancer. 2018 Jul;26(7):2379-2386 [PMID: 29423678]
  16. Blood. 2010 Mar 25;115(12):2508-19 [PMID: 20089962]
  17. Br J Clin Psychol. 2023 Mar;62(1):272-297 [PMID: 36536513]
  18. Cancer. 2000 Oct 1;89(7):1634-46 [PMID: 11013380]
  19. J Abnorm Psychol. 1986 Aug;95(3):274-81 [PMID: 3745650]
  20. Int J Psychophysiol. 2006 Nov;62(2):328-36 [PMID: 16905215]
  21. Health Psychol Rev. 2014;8(3):339-61 [PMID: 25053218]
  22. J Consult Clin Psychol. 1998 Feb;66(1):174-84 [PMID: 9489272]
  23. Health Psychol. 2014 Dec;33(12):1541-51 [PMID: 24274798]
  24. Bone Marrow Transplant. 2007 Jun;39(12):759-66 [PMID: 17438588]
  25. Semin Hematol. 2012 Jan;49(1):104-9 [PMID: 22221790]
  26. Emotion. 2016 Apr;16(3):349-64 [PMID: 26461252]
  27. Psychol Sci. 2003 Jul;14(4):320-7 [PMID: 12807404]
  28. Stem Cell Investig. 2021 Dec 14;8:24 [PMID: 35071585]
  29. J Behav Med. 2020 Jun;43(3):468-478 [PMID: 31863269]
  30. Blood. 2005 Oct 15;106(8):2912-9 [PMID: 15994282]
  31. Int J Environ Res Public Health. 2022 Apr 23;19(9): [PMID: 35564535]
  32. J Clin Oncol. 2007 Jan 1;25(1):163-6 [PMID: 17194913]
  33. J Behav Med. 2013 Apr;36(2):199-211 [PMID: 22481214]
  34. J Soc Clin Psychol. 2010 May 1;26(3):362-384 [PMID: 20824150]
  35. Psychosom Med. 1979 May;41(3):209-18 [PMID: 472086]
  36. J Clin Oncol. 2002 Oct 15;20(20):4160-8 [PMID: 12377959]
  37. Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501 [PMID: 23906634]
  38. Procedia Comput Sci. 2022;206:195-205 [PMID: 36567868]
  39. Complement Ther Med. 2016 Aug;27:87-101 [PMID: 27515882]
  40. Oncol Nurs Forum. 2016 Jul 1;43(4):468-79 [PMID: 27314189]
  41. Cochrane Database Syst Rev. 2019 Aug 08;8:CD006869 [PMID: 31425615]
  42. Ann Fam Med. 2015 Aug;13 Suppl 1:S42-9 [PMID: 26304971]
  43. J Abnorm Psychol. 2000 Feb;109(1):156-60 [PMID: 10740948]
  44. Support Care Cancer. 2017 Feb;25(2):421-427 [PMID: 27699502]
  45. Trials. 2021 Oct 20;22(1):722 [PMID: 34670600]
  46. J Nerv Ment Dis. 2004 Sep;192(9):629-34 [PMID: 15348980]
  47. PLoS One. 2015 Jul 07;10(7):e0131802 [PMID: 26151818]
  48. Support Care Cancer. 2019 Jun;27(6):2329-2337 [PMID: 30353229]
  49. Psychol Bull. 2006 Nov;132(6):823-65 [PMID: 17073523]
  50. Psychosomatics. 2019 Jul - Aug;60(4):331-342 [PMID: 31072626]
  51. Curr Oncol. 2019 Jun;26(3):187-191 [PMID: 31285665]
  52. Public Health Nurs. 1999 Apr;16(2):87-95 [PMID: 10319658]
  53. Psychooncology. 2022 Sep;31(9):1589-1596 [PMID: 35765696]
  54. J Clin Oncol. 2014 Mar 1;32(7):663-70 [PMID: 24470003]
  55. Psychooncology. 2015 Nov;24(11):1349-59 [PMID: 25871981]
  56. Health Educ Behav. 2022 Aug;49(4):667-679 [PMID: 34743575]
  57. Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10 [PMID: 36924931]
  58. Psychooncology. 2009 Feb;18(2):113-27 [PMID: 18677717]
  59. J Biopharm Stat. 2011 May;21(3):423-36 [PMID: 21442517]

Grants

  1. R01 CA223963/NCI NIH HHS
  2. /National Institutes of Health; National Cancer Institute

MeSH Term

Humans
Female
Male
Writing
Middle Aged
Quality of Life
Hematopoietic Stem Cell Transplantation
Adult
Cancer Survivors
Hematologic Neoplasms
Depression
Psychological Distress
Fatigue
Anxiety
Aged

Word Cloud

Created with Highcharts 10.0.0symptomsexpressiveinterventionwritinghelpingpersistenttrialtransplantperitransplantmonthsanalysescancerpatientsstemcellhealth-relatedqualitylifepriorrandomizedcontrolledsupportdistresslong-termsurvivorsusecompleteprimary12postinterventioneffectsModerationOBJECTIVE:undergoinghematopoieticreportelevatedreducedconcernscanbecomeshowedhelping-alow-burdenbriefcombiningnovelpeerexercise-reducedpsychologicalphysicalmoderate/highWritingInsightStrengthEaseevaluatedpeakearlypreventdevelopmentMETHOD:Threehundredsixty-sixadultblood443%female746%White134%Black115%Hispanic/Latinxscheduledallogeneic339%autologous661%eitherneutraltaskfoursessionsbeginningpretransplantending4weeksposthospitaldischargeSymptomseverityoutcomedepressivegeneralizedcancer-specificanxietyfatiguemeasuredmultipleassessmentsprerandomizationPrimaryendpoints3estimatedshort-exploredsubgroupdifferencesefficacyRESULTS:MixedmodelsrepeatedmeasuresrevealedstatisticallyclinicallysignificantsecondaryoutcomesidentifysubgroupsparticipantsbenefittedCONCLUSION:Findingsrecommendleast9posttransplantconsistentevidencePsycInfoDatabaseRecordc2025APArightsreservedEffectstransplant:Randomized

Similar Articles

Cited By

No available data.